Advertisement

Diabetologia

, Volume 61, Issue 10, pp 2215–2224 | Cite as

Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice

  • Andrew T. Templin
  • Daniel T. Meier
  • Joshua R. Willard
  • Tami Wolden-Hanson
  • Kelly Conway
  • Yin-Guo Lin
  • Patrick J. Gillespie
  • Krister B. Bokvist
  • Giorgio Attardo
  • Steven E. Kahn
  • Donalyn Scheuner
  • Rebecca L. Hull
Article

Abstract

Aims/hypothesis

Islet amyloid deposits contribute to beta cell dysfunction and death in most individuals with type 2 diabetes but non-invasive methods to determine the presence of these pathological protein aggregates are currently not available. Therefore, we examined whether florbetapir, a radiopharmaceutical agent used for detection of amyloid-β deposits in the brain, also allows identification of islet amyloid in the pancreas.

Methods

Saturation binding assays were used to determine the affinity of florbetapir for human islet amyloid polypeptide (hIAPP) aggregates in vitro. Islet amyloid-prone transgenic mice that express hIAPP in their beta cells and amyloid-free non-transgenic control mice were used to examine the ability of florbetapir to detect islet amyloid deposits in vitro, in vivo and ex vivo. Mice or mouse pancreases were subjected to autoradiographic, histochemical and/or positron emission tomography (PET) analyses to assess the utility of florbetapir in identifying islet amyloid.

Results

In vitro, florbetapir bound synthetic hIAPP fibrils with a dissociation constant of 7.9 nmol/l. Additionally, florbetapir bound preferentially to amyloid-containing hIAPP transgenic vs amyloid-free non-transgenic mouse pancreas sections in vitro, as determined by autoradiography (16,475 ± 5581 vs 5762 ± 575 density/unit area, p < 0.05). In hIAPP transgenic and non-transgenic mice fed a high-fat diet for 1 year, intravenous administration of florbetapir followed by PET scanning showed that the florbetapir signal was significantly higher in amyloid-laden hIAPP transgenic vs amyloid-free non-transgenic pancreases in vivo during the first 5 min of the scan (36.83 ± 2.22 vs 29.34 ± 2.03 standardised uptake value × min, p < 0.05). Following PET, pancreases were excised and florbetapir uptake was determined ex vivo by γ counting. Pancreatic uptake of florbetapir was significantly correlated with the degree of islet amyloid deposition, the latter assessed by histochemistry (r = 0.74, p < 0.001).

Conclusions/interpretation

Florbetapir binds to islet amyloid deposits in a specific and quantitative manner. In the future, florbetapir may be useful as a non-invasive tool to identify islet amyloid deposits in humans.

Keywords

Amyloid Diabetes Florbetapir Islet PET 

Abbreviations

CT

Computed tomography

GLP-1

Glucagon-like peptide-1

HFD

High-fat diet

hIAPP

Human islet amyloid polypeptide

PET

Positron emission tomography

SUV

Standardised uptake value

Notes

Acknowledgements

We thank M. Peters, B. Barrow, D. Hackney, P. Bergquist and J. Wilkins-Gutierrez (all Seattle Institute for Biomedical and Clinical Research, Seattle, WA, USA) for excellent technical assistance provided during these studies. We thank M. F. Hogan and S. Zraika (both Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, WA, USA) for critical review of the data generated in this study. Some data from this study were presented at the American Diabetes Association 77th Scientific Sessions in 2017.

Contribution statement

ATT acquired data, analysed/interpreted data and wrote the manuscript. DTM, JRW, TWH, KC, YG-L and PJG acquired data, analysed/interpreted data and reviewed/revised the manuscript. KBB and GA analysed/interpreted data and reviewed/revised the manuscript. SEK, DS and RLH designed the study, analysed/interpreted data and reviewed/revised the manuscript. All authors approved the final version of the manuscript to be published. ATT and RLH are responsible for the integrity of the work as a whole.

Funding

This work was supported by the Lilly Research Laboratories Early Discovery and Development Research Awards Program (to RLH), Department of Veterans Affairs (BX001060 to SEK), National Institutes of Health (F32DK107022 to ATT and Diabetes Research Center P30DK017047), American Diabetes Association (7-11-MN-28 to SEK) and the University of Washington (Dick and Julia McAbee Fellowship to DTM).

Duality of interest

This work was supported in part by an investigator-initiated research proposal from Lilly Research Laboratories (to RLH). SEK consulted for Eli Lilly & Co. during the performance of this study but did not receive compensation. At the time of the research, KC, Y-GL and GA were employees of Avid Radiopharmaceuticals, Inc., a subsidiary of Eli Lilly & Co. and PJG, KBB and DS were employees of and shareholders in Eli Lilly & Co. All other authors declare that there was no duality of interest associated with their contribution to this manuscript. The study sponsor was involved in the design of the study, collection and analysis of data, and editing the report. The sponsor was not involved in interpretation of data, writing the report or the decision to submit the report for publication.

Supplementary material

125_2018_4695_MOESM1_ESM.pdf (2 mb)
ESM (PDF 2027 kb)

References

  1. 1.
    Westermark P, Grimelius L (1973) The pancreatic islet cells in insular amyloidosis in human diabetic and non-diabetic adults. Acta Pathol Microbiol Scand 81:291–300Google Scholar
  2. 2.
    Jurgens CA, Toukatly MN, Fligner CL et al (2011) β-Cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 178:2632–2640CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Hull RL, Westermark GT, Westermark P, Kahn SE (2004) Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 89:3629–3643CrossRefPubMedGoogle Scholar
  4. 4.
    Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) β-Cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110CrossRefPubMedGoogle Scholar
  5. 5.
    Westermark GT, Davalli AM, Secchi A et al (2012) Further evidence for amyloid deposition in clinical pancreatic islet grafts. Transplantation 93:219–223CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Davalli AM, Perego L, Bertuzzi F et al (2008) Disproportionate hyperproinsulinemia, β-cell restricted prohormone convertase 2 deficiency, and cell cycle inhibitors expression by human islets transplanted into athymic nude mice: insights into nonimmune-mediated mechanisms of delayed islet graft failure. Cell Transplant 17:1323–1336CrossRefPubMedGoogle Scholar
  7. 7.
    Westermark P, Wernstedt C, Wilander E, Hayden DW, O’Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A 84:3881–3885CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84:8628–8632CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kahn SE, D’Alessio DA, Schwartz MW et al (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 39:634–638CrossRefPubMedGoogle Scholar
  10. 10.
    Verchere CB, D’Alessio DA, Palmiter RD et al (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci U S A 93:3492–3496CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Masters SL, Dunne A, Subramanian SL et al (2010) Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 11:897–904CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zraika S, Hull RL, Udayasankar J et al (2009) Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis. Diabetologia 52:626–635CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Zraika S, Aston-Mourney K, Marek P et al (2010) Neprilysin impedes islet amyloid formation by inhibition of fibril formation rather than peptide degradation. J Biol Chem 285:18177–18183CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Aston-Mourney K, Zraika S, Udayasankar J et al (2013) Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide. J Biol Chem 288:3553–3559CrossRefPubMedGoogle Scholar
  15. 15.
    Potter KJ, Scrocchi LA, Warnock GL et al (2009) Amyloid inhibitors enhance survival of cultured human islets. Biochim Biophys Acta 1790:566–574CrossRefPubMedGoogle Scholar
  16. 16.
    Hopping G, Kellock J, Barnwal RP et al (2014) Designed α-sheet peptides inhibit amyloid formation by targeting toxic oligomers. Elife 3:e01681CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Eriksson O, Laughlin M, Brom M et al (2016) In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use. Diabetologia 59:1340–1349CrossRefPubMedGoogle Scholar
  18. 18.
    Li J, Karunananthan J, Pelham B, Kandeel F (2016) Imaging pancreatic islet cells by positron emission tomography. World J Radiol 8:764–774CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Frey KA, Koeppe RA (2016) PET amyloid analyses. J Nucl Med 57:1168–1169CrossRefPubMedGoogle Scholar
  20. 20.
    Selvaraju RK, Velikyan I, Johansson L et al (2013) In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4. J Nucl Med 54:1458–1463CrossRefPubMedGoogle Scholar
  21. 21.
    Normandin MD, Petersen KF, Ding Y-S et al (2012) In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET. J Nucl Med 53:908–916CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Guo T, Brendel M, Grimmer T, Rominger A, Yakushev I (2016) Predicting regional pattern of longitudinal beta-amyloid accumulation by baseline positron emission tomography. J Nucl Med 58:639–645CrossRefPubMedGoogle Scholar
  23. 23.
    Insel PS, Mattsson N, Mackin RS et al (2016) Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. Neurology 86:1887–1896CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Nakamura T, Iwata A, Ueda K, Namiki C (2016) Clinical implications and appropriate use of amyloid imaging with florbetapir (18F) in diagnosis of patients with Alzheimer disease. Brain Nerve 68:1215–1222PubMedGoogle Scholar
  25. 25.
    Kayed R, Head E, Thompson JL et al (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486–489CrossRefPubMedGoogle Scholar
  26. 26.
    Yoshimura M, Ono M, Watanabe H, Kimura H, Saji H (2014) Feasibility of amylin imaging in pancreatic islets with β-amyloid imaging probes. Sci Rep 4:6155CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Yoshimura M, Ono M, Watanabe H, Kimura H, Saji H (2016) Development of 99mTc-labeled pyridyl benzofuran derivatives to detect pancreatic amylin in islet amyloid model mice. Bioconjug Chem 27:1532–1539CrossRefPubMedGoogle Scholar
  28. 28.
    Romano M, Buratti E (2013) Florbetapir F 18 for brain imaging of β-amyloid plaques. Drugs Today (Barc) 49:181–193Google Scholar
  29. 29.
    Yang L, Rieves D, Ganley C (2012) Brain amyloid imaging—FDA approval of florbetapir F18 injection. N Engl J Med 367:885–887CrossRefPubMedGoogle Scholar
  30. 30.
    Hull RL, Andrikopoulos S, Verchere CB et al (2003) Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52:372–379CrossRefPubMedGoogle Scholar
  31. 31.
    Meier DT, Morcos M, Samarasekera T, Zraika S, Hull RL, Kahn SE (2014) Islet amyloid formation is an important determinant for inducing islet inflammation in high-fat-fed human IAPP transgenic mice. Diabetologia 57:1884–1888CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Choi SR, Golding G, Zhuang Z et al (2009) Preclinical properties of 18F-AV-45: a PET agent for Aβ plaques in the brain. J Nucl Med 50:1887–1894CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Klunk WE, Wang Y, Huang G et al (2003) The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23:2086–2092CrossRefPubMedGoogle Scholar
  34. 34.
    D’Alessio DA, Verchere CB, Kahn SE et al (1994) Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43:1457–1461CrossRefPubMedGoogle Scholar
  35. 35.
    Trembath L, Newell M, Devous MD (2015) Technical considerations in brain amyloid PET imaging with 18F-florbetapir. J Nucl Med Technol 43:175–184CrossRefPubMedGoogle Scholar
  36. 36.
    Hull RL, Shen Z-P, Watts MR et al (2005) Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes 54:2235–2244CrossRefPubMedGoogle Scholar
  37. 37.
    Hull RL, Willard JR, Struck MD et al (2017) High fat feeding unmasks variable insulin responses in male C57BL/6 mouse substrains. J Endocrinol 233:53–64CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116:1802–1812CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Rhodes CJ (2005) Type 2 diabetes-a matter of β-cell life and death? Science 307:380–384CrossRefPubMedGoogle Scholar
  40. 40.
    Guardado-Mendoza R, Davalli AM, Chavez AO et al (2009) Pancreatic islet amyloidosis, β-cell apoptosis, and α-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci 106:13992–13997CrossRefPubMedGoogle Scholar
  41. 41.
    Guardado-Mendoza R, Perego C, Finzi G et al (2015) Delta cell death in the islet of Langerhans and the progression from normal glucose tolerance to type 2 diabetes in non-human primates (baboon, Papio hamadryas). Diabetologia 58:1814–1826CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443CrossRefPubMedGoogle Scholar
  43. 43.
    Kahn SE, Lachin JM, Zinman B et al (2011) Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes 60:1552–1560CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Aston-Mourney K, Subramanian SL, Zraika S et al (2013) One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. Am J Physiol Endocrinol Metab 305:E475–E484CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Nemmi F, Saint-Aubert L, Adel D et al (2014) Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer’s disease patients and healthy subjects. Eur J Nucl Med Mol Imaging 41:1408–1418CrossRefPubMedGoogle Scholar
  46. 46.
    Maclean N, Ogilvie RF (1955) Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes 4:367–376CrossRefPubMedGoogle Scholar
  47. 47.
    Hanley SC, Austin E, Assouline-Thomas B et al (2010) β-Cell mass dynamics and islet cell plasticity in human type 2 diabetes. Endocrinology 151:1462–1472CrossRefPubMedGoogle Scholar
  48. 48.
    Westermark P (1972) Quantitative studies on amyloid in the islets of Langerhans. Ups J Med Sci 77:91–94CrossRefPubMedGoogle Scholar
  49. 49.
    Clark A, Wells CA, Buley ID et al (1988) Islet amyloid, increased α-cells, reduced β-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9:151–159PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Andrew T. Templin
    • 1
    • 2
  • Daniel T. Meier
    • 1
    • 2
  • Joshua R. Willard
    • 1
    • 2
  • Tami Wolden-Hanson
    • 1
  • Kelly Conway
    • 3
  • Yin-Guo Lin
    • 3
  • Patrick J. Gillespie
    • 4
  • Krister B. Bokvist
    • 4
  • Giorgio Attardo
    • 3
  • Steven E. Kahn
    • 1
    • 2
  • Donalyn Scheuner
    • 4
  • Rebecca L. Hull
    • 1
    • 2
  1. 1.Department of MedicineVA Puget Sound Health Care SystemSeattleUSA
  2. 2.University of WashingtonSeattleUSA
  3. 3.Avid Radiopharmaceuticals, Inc.PhiladelphiaUSA
  4. 4.Eli Lilly Research LaboratoriesIndianapolisUSA

Personalised recommendations